For FY22, revenues from the generic API segment increased by 12.1% while the CDMO business saw revenues grow by 12.4%. While regulated market revenues grew 21.4%, the emerging market revenues fell by -6.3%.
The board has recommended a final dividend of Rs.10.50/share, taking the total dividend to Rs.21.
While input costs were an issue, the emerging markets business also took a dip on profits. EBITDA margins at 28.7% in Q4 were up 10 bps on a yoy basis but 770 bps lower on a sequential basis.
Ratio of regulated to emerging markets is 72:28. Net margins for stood at 19.24% in Mar-22 quarter compared to 22.41% in Mar-21. The net profit margins were also lower by 611 basis points on a sequential basis.
Financial highlights for Mar-22 compared yoy and sequentially
Glenmark Life Sciences | |||||
Rs in Crore | Mar-22 | Mar-21 | YOY | Dec-21 | QOQ |
Total Income (Rs cr) | ₹ 514.06 | ₹ 467.16 | 10.04% | ₹ 522.50 | -1.62% |
Net Profit (Rs cr) | ₹ 98.90 | ₹ 104.68 | -5.52% | ₹ 103.71 | -4.64% |
Diluted EPS (Rs) | ₹ 8.07 | ₹ 9.71 | ₹ 8.65 | ||
Net Margins | 19.24% | 22.41% | 19.85% |
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.